We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy
News

Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy

Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy
News

Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nanostart majority-owned MagForce announces successful completion of phase II clinical trials for Nano-Cancer® therapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

According to a previous study among a large patient population, the median survival time following diagnosis of a glioblastoma recurrence and treatment with conventional therapy (surgery, chemotherapy and radiation) is 6.2 months. The primary objective for the Nano-Cancer® therapy study was to demonstrate an extension of the median survival time in the recruited patient group by three months compared to this historical control group.

In fact, the median survival time of the 59 patients participating in the phase II clinical trials was 13.4 months following treatment with Nano-Cancer® therapy in conjunction with radiation. The median survival time was thus significantly greater, more than double that of the control population.

The results were even more remarkable in that Nano-Cancer® therapy was tested not on newly diagnosed patients with primary tumors but rather as a study involving patients who had already endured treatment with conventional therapies, as well as the unpleasant effects generally associated with these. Following regulatory approval of the new therapy, it is expected that it will also be available for use in treating other types of localized tumors, as these are generally responsive to the same principle of using warmth to destroy or degrade cancer cells.
Advertisement